Abstract Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is efficacious as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Dosage reduction is recommended in patients with intolerable adverse events; however, data regarding the efficacy of low-dose afatinib are limited. We report the case of a 71-year-old female patient who was diagnosed with advanced EGFR-mutated NSCLC and started treatment with oral afatinib 40 mg daily. The patient achieved partial tumor response on computed tomography imaging, but developed unacceptable skin-related toxicities requiring dosage reduction to 20 mg daily. The patient subsequently achieved complete tumor response and showed improvements in performance status. These observations suggest that low-dose afatinib is effective in patients with EGFRmutated NSCLC who require dosage reduction for intolerable adverse events.
The second-generation tyrosine kinase inhibitor afatinib, at 40 mg daily, effectively prolongs progression-free survival when used as first-line therapy in patients with epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Afatinib is often associated with adverse events, including skin rash, diarrhea, and stomatitis, that may require dosage reduction.
Although randomized clinical studies with afatinib have permitted dosage reductions for adverse events to 20 mg daily, clinical data regarding the efficacy of afatinib 20 mg daily in NSCLC are limited.
In this case report, low-dose afatinib (20 mg daily) provided complete tumor response in a patient with advanced EGFR-mutated NSCLC who experienced intolerable skin-related toxicities while receiving higher afatinib dosages.
Low-dose afatinib may be an effective option for patients with advanced EGFR-mutated NSCLC who develop intolerable adverse events at higher dosages.
Introduction
Afatinib is a second-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) [1] , and is approved for the first-line treatment of advanced EGFRmutated non-small cell lung cancer (NSCLC) [2] [3] [4] . As with other EGFR tyrosine kinase inhibitors (TKIs), the most common adverse events with afatinib are diarrhea, skin rash, paronychia, and stomatitis. The grade and the severity of drug toxicity can lead to dosage reduction or permanent treatment discontinuation. According to labeling recommendations, the starting dosage of afatinib should be 40 mg daily, although dosage reduction to 30 or 20 mg daily is possible if treatment is not tolerated [2] [3] [4] .
In the first-line treatment of EGFR-mutated NSCLC, randomized clinical studies have demonstrated the superior efficacy of afatinib 40 mg daily in prolonging progressionfree survival (PFS) compared with the first-generation EGFR TKI gefitinib [5] and cisplatin-based chemotherapy [6, 7] . Although these studies permitted afatinib dosage reductions to 20 mg daily for treatment-related adverse events of grade 3 or higher (or prolonged grade 2 events), clinical data regarding the efficacy of afatinib 20 mg daily in NSCLC are limited.
We report our experience with a patient with advanced EGFR-mutated NSCLC who achieved complete tumor response with afatinib 20 mg daily, after intolerable adverse events developed at higher afatinib dosages.
Case Report
A 71-year-old female was admitted to an emergency department for dysphonia and dyspnea. The patient's medical history included hypertension and osteoarthritis; she had never smoked. Total body computed tomography (CT) imaging showed a thoracic mass in the superior left lobe, with multiple small bilateral nodules and pleural effusion (Fig. 1a) , but was negative for abdominal, brain, or bone metastases. Based on bronchoscopy with biopsy findings, the patient was diagnosed with EGFR-mutated (Exon 21, L858R) NSCLC adenocarcinoma, cT4 N2 M0, stage IV according to the American Joint Committee on Cancer staging system, 7th edition [8] . The patient underwent palliative thoracentesis to manage dyspnea, from which cytology examination detected NSCLC cells. Surgery was excluded because of bilateral lung metastases and pericardial involvement. Considering the tumor histological and biological features and the patient's good Karnofsky Performance Status (KPS) score (70% at diagnosis), first-line treatment with oral afatinib 40 mg daily was initiated.
After 2 months of afatinib 40 mg daily, the patient presented with several adverse events based on Common Terminology Criteria for Adverse Events (4.03 version): grade 3 skin rash (Fig. 2a, b) , grade 3 mucositis, grade 2 diarrhea, and grade 2 paronychia. In accordance with labeling information, afatinib therapy was interrupted and the patient was admitted to the oncology department for further treatment. During hospitalization, CT imaging showed partial response to afatinib therapy (Fig. 1b) . After dermatologic consultation, the patient started intravenous and topical antibiotic (amoxicillin/clavulanic acid) and antimycotic (fluconazole) treatment, as well as topical 3% boric acid solution. Ten days later, her skin rash and mucositis had regressed to grade 2, with complete resolution of gastrointestinal toxicities.
Twenty days after treatment interruption, the patient restarted afatinib therapy at a reduced dosage of 30 mg daily. Eight months after starting afatinib therapy, CT imaging showed further partial response compared with the previous scan, with resolution of the pleural effusion and (Fig. 1c) . The patient's dysphonia had also improved. However, she continued to present with grade 2 skin rash with infected lesions. The afatinib dosage was further reduced to 20 mg daily, and the patient started empiric antibiotic treatment with oral doxycycline 100 mg twice daily until toxicity improved to grade 1.
After 3 months of afatinib 20 mg daily (i.e., 11 months after starting afatinib therapy), positron emission tomography-CT imaging showed complete regression of the tumor (Figs. 1d, 3) . The patient's dyspnea had completely recovered and she had an estimated KPS of 80%. At this time, we observed complete resolution of skin toxicity (grade 0, Fig. 2c, d ) and the patient reported only grade 1 diarrhea.
At last follow-up, the patient had no local or systemic recurrence of disease and PFS was about 11 months.
Discussion
Patients with advanced NSCLC, if untreated, have an estimated median survival of 4-5 months following diagnosis [9] . Historically, first-line treatment for NSCLC has Fig. 2 a, b Grade 3 skin rash developed after 2 months of afatinib 40 mg daily with macules/papules covering [30% of body-surface area with associated pain and limiting self-care. c, d Complete resolution of skin rash after 3 months of afatinib 20 mg daily without local or systemic recurrence of non-small cell lung cancer Fig. 3 Positron emission tomography imaging after 11 months of afatinib therapy been platinum-based chemotherapy, which provides a modest improvement in survival but carries a high risk of toxicity [9, 10] . In patients with EGFR-mutated NSCLC, EGFR TKIs, such as afatinib, are superior to conventional chemotherapy with respect to overall response, PFS, and quality of life [10] , and are recommended as first-line therapy [11] .
Diarrhea and skin-related toxicities with afatinib are common and can often lead to dosage reduction or treatment discontinuation. According to afatinib labeling information, treatment should be interrupted for prolonged or intolerable grade 2 diarrhea or skin-related events or any adverse event of grade 3 or higher [2] [3] [4] . After the adverse event has resolved or improved to grade 1, afatinib can be resumed at a reduced dosage (i.e., 10 mg/day lower), but should be permanently discontinued in patients who experience unacceptable toxicities at 20 mg daily [2] [3] [4] .
In this case report of a patient with advanced EGFRmutated NSCLC, complete tumor response was achieved with afatinib after the dosage was reduced to 20 mg daily for intolerable skin-related toxicities. At the time of the patient's first visit, final data on head-tohead comparisons of afatinib versus gefitinib or erlotinib were not available. Treatment with afatinib was initiated because its broad spectrum of activity and irreversible mechanism of action had been postulated to be associated with improved inhibition of EGFR-dependent tumor growth compared with first-generation EGFR TKIs. Furthermore, the availability of different dosages allowed for better management of drug-related adverse reactions.
Although data on the use of afatinib 20 mg daily are limited, our observations are consistent with a previous case report [12] and clinical study [13] . In the previous case, afatinib 20 mg/day in combination with prednisolone was associated with primary tumor size reduction and improvement in carcinomatous lymphangitis in a patient with NSCLC adenocarcinoma [12] . In a clinical study of afatinib 40 mg daily [5] , post-hoc analysis of 160 patients showed that 39% required dosage reduction to 30 mg daily and 13% had a further dosage reduction to 20 mg daily [13] . However, patients who received afatinib at a reduced dose showed no significant difference in median PFS and a reduction in the incidence and severity of drug-related adverse events compared with those who received 40 mg or higher. This suggests that dosing of afatinib can be adjusted to help manage treatment-related adverse events, without any apparent reduction in efficacy. This may provide physicians and their patients with confidence and allow physicians to better address adverse events.
Conclusion
Low-dose afatinib may be effective in patients with EGFRmutated NSCLC who develop unacceptable toxicities at higher dosages. Further studies investigating the efficacy of afatinib 20 mg daily in EGFR-mutated NSCLC are warranted.
